Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ya took quite the haircut yesterday, little bugger
well, who knows what was happening yesterday, but it's turning out to be a good little flipper stock....
.85 x .857 and yet someone just bought 2300 at .88...FRP
wow, it went pink.....
tty next year, lol
NSTR .10 annie..lol evry year we can chat about it..
EESO down 43% at the moment...guess the pump job didn't work...obviously some bagholders in there now, unfortunately....
Tip: don't drink the kool-aid!
Hi Mary, think I sold them around 1.65 if I remember right...boy, this board been quite a lonnnng time, lol!
that's nice what did u sell them at? 1.19 now lol
NSTR sold my freebies
out...green, am surprised, lol!
FNMM FinMetal Drilling Intersects Significant Nickel Zone at Halvala, Finland
Friday, March 14 2008 9:00 AM, EST Market Wire "US Press Releases "TAMPERE, FINLAND -- (MARKET WIRE) -- 03/14/08 -- FinMetal Mining Ltd. (OTCBB: FNMM) has announced assay results from the first diamond drill hole of a two hole preliminary evaluation in its joint venture with Magnus Minerals at the Halvala nickel exploration prospect located in the Enonkoski Belt in Finland .
In late December, the company began its preliminary evaluation drilling at Halvala. In late February, the company completed the first two, 600 meter holes; numbered FML-01 and FML-02. Hole FML-01 intersected 12.23 meters of nickel sulphide mineralization at a depth of 550m with an average grade of 0.93% nickel that includes an interval of 2.07% nickel and 0.43% copper over 4.83 meters.
Assay results are pending on nickel sulphide mineralisation intersected at a depth of approximately 500m in FML-002 drilled about 50 m away from FML-001 in order to test the continuity of the mineralization. The significance of the intersections in both holes will be evaluated when assays are received from this second hole; however FinMetal's three dimensional compilation of the historical data at Halvala indicates that both sulphide intersections are part of a vertical cylinder-shaped zone of nickel sulphides open at depth.
Steve Balch, Vice President Exploration of FinMetal, said today, "This result is consistent with our expectations for Halvala -- both good grade and good thickness at this depth. Halvala is a highly prospective brown field site with excellent infrastructure where some nickel has been mined in the past. Our objective is to establish reserves that may be mined deeper underground."
Halvala is the first of four high priority targets identified by FinMetal in its Finnish nickel exploration program based upon earlier work performed by the Geological Survey of Finland (GTK). In addition a 6,500 line kilometer airborne electromagnetic survey conducted by FinMetal in late 2007 has identified a number of anomalies that may reflect hidden massive nickel sulphides because of their high conductance and association with prospective geology.
On Behalf of the Board:
Daniel Hunter - CEO
FinMetal Mining Ltd.
Finlaysoninkuja 9
FIN-33210 Tampere, Finland
Phone: +358 3 260 4331
Fax: +358 3 260 4330
e-mail: info@finmetalmining.com
www.FinMetalMining.com
Disclaimer
This release contains forward-looking statements that are based on the beliefs of FinMetal Mining Ltd.'s management and reflect FinMetal Mining Ltd.'s current expectations as contemplated under section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. When used in this release, the words "estimate," "project," "believe," "anticipate," "intend," "expect," "plan," "predict," "may," "should," "will," "can," the negative of these words, or such other variations thereon, or comparable terminology, are all intended to identify forward-looking statements. Such statements reflect the current views of FinMetal Mining Ltd. with respect to future events based on currently available information and are subject to numerous assumptions, risks and uncertainties, including, but not limited to, risks and uncertainties pertaining to development of mining properties, changes in economic conditions and other risks, uncertainties and factors, which may cause the actual results, performance, or achievement expressed or implied by such forward-looking statements to differ materially from the forward-looking statements.
Daniel Hunter
CEO
FinMetal Mining Ltd.
Finlaysoninkuja 9
FIN-33210 Tampere, Finland
Phone: +358 3 260 4331
Fax: +358 3 260 4330
e-mail: info@finmetalmining.com
www.FinMetalMining.com
Northstar Neuroscience Schedules Fourth Quarter and Full Year 2007 Earnings Release and Conference Call for Thursday March 6, 2008
Thursday February 28, 3:00 pm ET
SEATTLE--(BUSINESS WIRE)--Northstar Neuroscience, Inc. (NASDAQ: NSTR - News) announced today that it plans to release fourth quarter and full year 2007 financial results after market close on Thursday March 6, 2008. Management will hold a conference call starting at 4:30 p.m. EST (1:30 p.m. PST) on the same day. The conference call will be concurrently Web cast.
up 40% at the close
NSTR, someone just bought 10K at 1.80....sweet, 1.77 x 1.79
ACUS, up 14%, riding free shares now
ACUS .542 x .5476, wish CINN would go away
NSTR, 1.60 x 1.62
NSTR still got my freebies
ACUS just got the sar drop....59 x 60
ACUS some nice sized buys coming in...good volume today
NSTR 1.51 x 1.52, up 10%
Merry Christmas Merci!
Merry Christmas my little buddie... miss ya
PPHM news...PPHM Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer
Sep 4, 2007 08:30:00 (ET)
TUSTIN, Calif., Sept 04, 2007 /PRNewswire-FirstCall via COMTEX/ -- Peregrine Pharmaceuticals, Inc. (PPHM, Trade ), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today reported that researchers have published a new study in a lung cancer model showing that the combination of a mouse equivalent of bavituximab and radiation is significantly more effective in reducing tumor growth than either therapy alone. The study was published in the September 1 issue of Clinical Cancer Research. Bavituximab, Peregrine's lead anti-phosphatidylserine (anti-PS) immunotherapy, is currently in clinical trials for the treatment of solid tumors including lung cancer.
"This new publication further supports the concept that radiation therapy and bavituximab may work synergistically to treat solid tumors." said Steven W. King, president and CEO of Peregrine. "We are particularly pleased to see these positive results in a model of radiation resistant lung cancer, by far the leading cause of U.S. cancer deaths. This is the latest in a series of preclinical studies that have demonstrated the potential of either radiation or chemotherapy to enhance bavituximab's anti-tumor effects. We look forward to evaluating a combination of bavituximab plus radiation therapy in future clinical studies."
Peregrine completed a pilot Phase I study evaluating bavituximab in combination with chemotherapy in advanced cancer patients earlier this year and reported promising results. Based on these results, Peregrine recently submitted a Phase II clinical protocol to test bavituximab plus carboplatin/paclitaxel in lung cancer patients and plans to file several additional combination therapy clinical protocols this year.
Lung cancer is the leading cause of cancer deaths in the U.S. with a 5-year survival rate of only about 15%. With more than one million new cases diagnosed worldwide each year, lung cancer is also the leading cause of cancer deaths globally. About half of all lung cancer patients receive radiation therapy, but many become resistant to its tumor-killing effects. In this study, researchers tested a bavituximab equivalent combined with radiation therapy in a radiation-resistant mouse model of lung cancer.
The UT Southwestern Medical Center researchers found that in this lung cancer model, radiation therapy increased by over six-fold the percentage of tumor blood vessel cells that exposed bavituximab's PS target on the external surfaces. As a result, more of the bavituximab equivalent antibodies became concentrated in the tumor blood vessels. This increased localization may have contributed to the finding that the density of tumor blood vessels was reduced by more than 90% and tumor growth was reduced by 80% in animals treated with combination therapy, significantly greater efficacy than was achieved with either treatment alone.
"Approximately 50% of all cancer patients receive radiation therapy, so these findings could potentially apply to millions of patients," noted Dr. Philip Thorpe, professor of pharmacology at UT Southwestern and a member of Peregrine's Scientific Resource Board. "We are also pleased that these results confirm our previous work that demonstrated that the enhanced therapeutic effects of bavituximab combination therapy do not appear to be accompanied by an increase in side effects, offering the possibility of more effective and less toxic anti-cancer regimens."
Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is normally located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobilize the body's immune system to destroy the blood vessels needed for tumor growth and spread. In a Phase lb trial in advanced cancer patients bavituximab plus chemotherapy appeared to have a safety profile consistent with chemotherapy alone and showed positive signs of clinical activity. In the study, objective response or disease stabilization was achieved in 50% of patients evaluated for tumor response. A protocol for a Phase ll trial of bavituximab in combination with chemotherapy in patients with non-small cell lung cancer (NSCLC) has been filed and is currently undergoing regulatory review. Bavituximab is also in clinical trials in the U.S. in patients with advanced solid tumors and in patients co-infected with HCV and HIV.
The study, titled 'Radiation-Enhanced Vascular Targeting of Human Lung Cancers in Mice with a Monoclonal Antibody That Binds Anionic Phospholipids," was co-authored by Philip Thorpe, Jin He, and Troy A. Luster. The research was funded with assistance from the Gillson Longenbaugh Foundation and the American Cancer Society.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ( http://www.avidbio.com ), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com .
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that results of human studies will not correlate to the results achieved in connection with the preclinical lung cancer model, the uncertainty as to whether the results of future clinical studies will support moving this product candidate forward for the treatment of lung cancer. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Contacts:
GendeLLindheim BioCom Partners
Investors Media
info@peregrineinc.com Barbara Lindheim
(800) 987-8256 (212) 918-4650
TUSTIN, Calif., July 9 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that it has licensed worldwide exclusive rights to a novel anti-angiogenesis technology from The University of Texas M. D. Anderson Cancer Center. The agreement is for development and commercialization rights to all forms of "clipped" (or nicked) Beta 2 Glycoprotein 1 (B2GP1) protein, which was first characterized by Dr. Alan J. Schroit, Deputy Chairman, Department of Cancer Biology and John Q. Gaines Professor of Cancer Biology at M. D. Anderson Cancer Center. Peregrine, Dr. Schroit and M. D. Anderson will collaborate under a sponsored research agreement to conduct preclinical studies that are designed to advance B2GP1 toward human clinical trials.
The anti-cancer potential of clipped B2GP1 has been independently verified in a study published in September 2006 by a group of authors that included angiogenesis pioneer Dr. Judah Folkman. They showed that clipped B2GP1 inhibited endothelial cell proliferation and tube formation and reduced tumor growth by 96% in an animal model of bladder cancer.(1)
"A growing body of studies suggests that clipped Beta 2 Glycoprotein 1 is a promising anti-angiogenic agent. We are delighted to have secured the rights to develop and market potential new therapies based on this approach," said Steven W. King, president and CEO of Peregrine. "We are particularly encouraged by the fact that we have already identified a potential clinical candidate for the B2GP1 program, and we look forward to working with Dr. Schroit and his colleagues at M. D. Anderson to complete the preclinical studies needed to move clipped B2GP1 toward clinical testing in humans."
"Clipped forms of Beta 2 Glycoprotein 1 may represent an exciting new approach for anti-angiogenesis therapies, and I am pleased to be collaborating with Peregrine to further explore its clinical utility," said Dr. Schroit. "The more we learn about this plasma protein, the more intriguing its role appears to be. The anti-angiogenic potential of B2GP1 was first identified by my laboratory in studies suggesting that it is a negative regulator of angiogenesis that can inhibit the growth of primary tumors and metastases. First-generation anti-angiogenesis agents have already demonstrated their value in some cancer and ophthalmology applications, and we are eager to learn more about the clinical potential of this new anti-angiogenesis approach."
(1): An Endogenous Inhibitor of Angiogenesis derived from a Transitional Cell Carcinoma: Clipped b2-Glycoprotein-I Wolf-Dietrich C. Beecken,1 Tobias Engl,1 Eva M. Ringel,1 Kevin Camphausen,2 Martin Michaelis,3 Dietger Jonas,1 Judah Folkman,4 Yuen Shing,4 and Roman A. Blaheta1 Annals of Surgical Oncology, 13(9): 1241--1251
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection in the U.S. and India with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (http://www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at http://www.peregrineinc.com.
Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the results from future preclinical studies will not correlate with the results from the animal model of bladder cancer and the risk that future results will not support moving this drug candidate into human clinical trials. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the Company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2006 and the quarterly report on Form 10-Q for the quarter ended January 31, 2007. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
Contacts:
GendeLLindheim BioCom Partners
Investors Media
info@peregrineinc.com Barbara Lindheim
(800) 987-8256 (212) 918-4650
SOURCE Peregrine Pharmaceuticals, Inc.
TZMT, lots of volume there today, up 3.75%, wonder why...just have some freebies from long ago
wishing TF would let me buys bb's online, grrrr
riding free now....70 x 704
MCEL 68 x 6889, just got the dot
AVANT's Partner, GlaxoSmithKline, Files Rotarix(R) Application for U.S. Marketing Approval with the FDA
Wednesday June 27, 8:00 am ET
NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN - News) today announced that its partner, GlaxoSmithKline (GSK) Biologicals, has filed a marketing application for the Rotarix® vaccine with the United States Food and Drug Administration (FDA). Rotarix® is a two-dose rotavirus vaccine given to children for the prevention of gastroenteritis caused by rotavirus.
ADVERTISEMENT
"We are delighted that our partner GSK has filed for approval of Rotarix® in the United States," said Una S. Ryan, Ph.D., President and Chief Executive Officer of AVANT Immunotherapeutics. "The FDA filing marks a significant milestone towards the global commercialization of Rotarix®, which has already been approved for commercial use in over 90 countries worldwide, including the European Union."
In May 2005, AVANT entered into an agreement whereby an affiliate of Paul Royalty Fund (PRF) purchased an interest in the net royalties AVANT will receive on worldwide sales of Rotarix®. The terms of the agreement with PRF include a $10 million milestone payment on product launch in 2008 in the United States. Under the PRF agreement, AVANT retains 50% of the GSK milestone payment triggered by U.S. approval of Rotarix®, with the balance payable to PRF and Cincinnati Children's Hospital Medical Center.
About Rotarix®
Rotarix® is an oral, two-dose, live attenuated vaccine against rotavirus disease in infants that was licensed in 1997 by AVANT Immunotherapeutics to GSK for worldwide commercialization. The vaccine was originally developed at Cincinnati Children's Hospital Medical Center. Rotarix® is the first human rotavirus vaccine derived from a human virus strain available in the market. The vaccine, which is given orally, confers significant protection against rotavirus diarrhea. Clinical trials have shown high efficacy against the most prevalent rotavirus strains. It is given in a two-dose schedule as of six weeks of age, allowing for early protection.
About AVANT Immunotherapeutics, Inc.
AVANT Immunotherapeutics, Inc. discovers and develops innovative vaccines and therapeutics that harness the human immune system to prevent and treat disease. AVANT has three products on the market and four of AVANT's products are in clinical development. AVANT's pipeline includes products for travelers' vaccines and global health needs based on AVANT's oral, rapid-protecting, single-dose and temperature-stable vaccine technology.
Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: http://www.avantimmune.com.
AVAN coming along nicely....got the SAR today
Zarlink to Buy Legerity
Monday June 25, 5:26 pm ET
Zarlink Semiconductor to Buy Legerity Holdings for $134.5 Million
NEW YORK (AP) -- Canadian communications chip maker Zarlink Semiconductor Inc. said Monday it agreed to pay $134.5 million in cash to buy Legerity Holdings Inc.
Ottowa-based Zarlink said its purchase of the privately held voice-integrated circuit company will speed up and expand its plans for the voice-over Internet and cable markets.
up another 9%
super sweet....up 41%
TMTA, now .457 x 46, 17%...sweet
TMTA slowly, up 9%
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |